PI3K inhibitors as potential therapeutics for autoimmune disease

Jennifer Ball, Sophie Archer, Stephen Ward

Research output: Contribution to journalArticlepeer-review

29 Citations (SciVal)
317 Downloads (Pure)


Aberrant overactivation of the immune system can give rise to chronic and persistent self-attack, culminating in autoimmune disease. This is currently managed therapeutically using potent immunosuppressive and anti-inflammatory drugs. Class I phosphoinositide 3-kinases (PI3Ks) have been identified as ideal therapeutic targets for autoimmune diseases given their wide-ranging roles in immunological processes. Recent studies into the function of selective PI3K inhibitors in vitro and in vivo have yielded encouraging results, allowing progression into the clinic. Here, we review their recent progress across a range of autoimmune diseases.
Original languageEnglish
Pages (from-to)1195-1199
Number of pages5
JournalDrug Discovery Today
Issue number8
Early online date13 Apr 2014
Publication statusPublished - Aug 2014


Dive into the research topics of 'PI3K inhibitors as potential therapeutics for autoimmune disease'. Together they form a unique fingerprint.

Cite this